The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals has analysts doing financial backflips as they boost its price targets, with Royal Bank of Canada ...

Despite missing this important feature—promised at WWDC last fall—there are lots of improvements in iOS 18.4. The iOS 18.4 beta began on February 21 with a developer beta, and the first public ...

DiveWire guarantees visibility for your news announcements through instant distribution to CIO Dive’s audience and its 89,500 newsletter subscribers for 21 days.

At the recent groundbreaking ceremony for the Kiunga Airport Upgrade, James Donald, the Member for North Fly, expressed concerns regarding the future of his people in the district and province, ...